<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4418">
  <stage>Registered</stage>
  <submitdate>24/04/2014</submitdate>
  <approvaldate>24/04/2014</approvaldate>
  <nctid>NCT02124746</nctid>
  <trial_identification>
    <studytitle>Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia</studytitle>
    <scientifictitle>Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2013-004476-36</secondaryid>
    <secondaryid>GS-US-352-1154</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Primary Myelofibrosis</healthcondition>
    <healthcondition>Post-Polycythemia Vera Myelofibrosis</healthcondition>
    <healthcondition>Post-Essential Thrombocythemia Myelofibrosis</healthcondition>
    <healthcondition>Polycythemia Vera</healthcondition>
    <healthcondition>Essential Thrombocythemia</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Momelotinib

Experimental: Cohort 1 - Participants previously enrolled in Study CCL09191E will receive momelotinib for up to 4 years.

Experimental: Cohort 2 - Participants previously enrolled in Study YM387-II-02 will receive momelotinib for up to 4 years.

Experimental: Cohort 3 - Participants previously enrolled in Study GS-US-354-0101 will receive momelotinib for up to 4 years.
Cohort 3 was closed and all enrolled participants were discontinued from this study because parent Study GS-US-354-0101 was terminated.

Experimental: Cohort 4 - Participants previously enrolled in Study GS-US-352-1672 will receive momelotinib for up to 4 years.


Treatment: drugs: Momelotinib
Momelotinib tablets administered orally once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Adverse event profile of momelotinib as measured by incidence and severity of adverse events - This endpoint will measure the long-term safety and tolerability profile of momelotinib; safety information will include safety data collected after the first dose of momelotinib from the previous study.</outcome>
      <timepoint>Up to 4 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Laboratory abnormality profile of momelotinib as measured by incidence and severity of clinical laboratory abnormalities - This endpoint will measure the long-term safety and tolerability profile of momelotinib; safety information will include safety data collected after the first dose of momelotinib from the previous study.</outcome>
      <timepoint>Up to 4 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival - Overall survival (OS) is defined as the interval from the first dose of momelotinib on the previous study until death from any cause.</outcome>
      <timepoint>Up to 4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival - Progression-free survival (PFS) is defined as the interval from the first dose of momelotinib on the previous study until the first documentation of definitive progressive disease or death due to any cause.
Progressive disease for Cohorts 1 &amp; 2 is defined as leukemic transformation, increase in peripheral blood blast for at least 8 weeks, or progressive splenomegaly.</outcome>
      <timepoint>Up to 4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Leukemia-free survival - Leukemia-free survival is defined as the interval from the first dose of momelotinib on the previous study until the first documented leukemic transformation or death from any cause.</outcome>
      <timepoint>Up to 4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of RBC transfusion - Rate of red blood cell (RBC) transfusion is defined as the average number of RBC units per subject month from the first dose of momelotinib on the previous study during the study period.</outcome>
      <timepoint>Up to 4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of splenic response (Cohorts 1 and 2 only) - Duration of splenic response is defined as the interval from the first onset of splenic response (in the previous study or this study) to loss of splenic response for = 4 weeks or death from any cause.
Splenic response is defined as:
&gt; 50% reduction in palpable splenomegaly of a spleen that is = 10 cm below the left costal margin (LCM) at baseline or
a spleen becomes not palpable, that is palpable at &gt; 5 cm below the LCM at baseline</outcome>
      <timepoint>Up to 4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of transfusion independence response (Cohorts 1 and 2 only) - Duration of transfusion independence response is defined as the interval from the first onset date of transfusion independence (in the previous study or this study) to the earliest onset date of transfusion dependence or death from any cause for participants who are transfusion dependent at baseline.
Transfusion independence is defined as absence of RBC transfusions for = 12 weeks.</outcome>
      <timepoint>Up to 4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of anemia response (Cohorts 1 and 2 only) - Duration of anemia response is defined as the interval from the first onset of anemia response to the earliest date of loss of anemia response which persists for at least 4 weeks, or death from any cause
Anemia response is defined as:
= 2 g/dL increase in hemoglobin, if transfusion independent and with hemoglobin level of &lt; 10 g/dL at baseline
Achieving transfusion independence for = 12 weeks, if transfusion dependent at baseline</outcome>
      <timepoint>Up to 4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Transfusion response rate (Cohort 4 only) - Transfusion response rate is defined as becoming not transfusion dependent for = 12 weeks at any time from the first dose of MMB on the previous study until end of this study.</outcome>
      <timepoint>Up to 4 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Currently enrolled in study CCL09101E, or YM387-II-02, or successfully completed 24
             weeks of study GS-US-352-1672

          -  Able to comprehend and willing to sign informed consent form

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known hypersensitivity to momelotinib, its metabolites, or formulation excipients

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>30/04/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>105</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital> - Frankston</hospital>
    <hospital> - Parkville</hospital>
    <postcode> - Frankston</postcode>
    <postcode> - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Tronche</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Minden</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This open-label study is to determine the long-term safety and tolerability of momelotinib in
      previously enrolled study participants with primary myelofibrosis (PMF), post-polycythemia
      vera myelofibrosis (post-PV MF), post-essential thrombocythemia myelofibrosis (post-ET MF),
      polycythemia vera (PV), or essential thrombocythemia (ET), who have tolerated and achieved
      stable disease or better with momelotinib treatment while enrolled in a previous clinical
      trial.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02124746</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gilead Study Director</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>